alkylation of LY264826 (A82846B) provide the most potent derivatives as compared to other members of this class of antibiotics.
Two of these derivatives, LY307599 and LY333328 are approximately 500 times more active than vancomycin against vancomycin-resistant enterococci.
The glycopeptide antibiotic vancomycin has been an important drug for the treatment of Gram-positive bacteria since being introduced 35 years ago. As a result of resistance to other antibiotics, vancomycinis nowthe drug of choice for the treatment of serious Gram-positive infections.
In the late 1980' s, however, enterococci resistant to vancomycin were encountered,1>2) creating a situation for which there is essentially no treatment available for some of these infections. While resistance to vancomycin has not yet spread to staphylococci or streptococci in the clinic, experts agree it maybe only a matter of time. The resistance to enterococci alone has nonetheless created an urgent need for the development of new therapies.
Previous reports have demonstrated that JV-alkylation of the vancosaminyl moiety of vancomycin can result in enhanced activity, 3) and in some cases, restore the effectiveness of the glycopeptide toward vancomycinresistant enterococci (50-fold increase in activity).40
While this is indeed important work, these semisynthetic vancomycin derivatives lack the potency necessary for further development. These studies established that, under these reaction conditions (alkyl halide, NaHCO3), substitution occurs preferentially at the 7V-methylleucine moiety, followed by alkylation of the carboxyl group to afford ester derivatives. These substitutions resulted in comparable or lower antibacterial activity against Gram-positive bacteria as compared to vancomycin and eremomycin, however all derivatives were inactive against vancomycinresistant enterococci. Herein we report our findings for the selective monoalkylation of the glycopeptide antibiotic LY264826 by reductive alkylation and the application of this methodology to other structurally-related natural glycopeptides. Of significance, we found that 7V-alkylation of LY264826 on the disaccharide amino function offered the greatest advantage and presents a promising outlook for successfully negotiating the resistance mechanisms presented by the enterococci.
Chemistry The A82846 family of glycopeptide antibiotics are structurally similar to vancomycin, the major difference being the presence of an additional sugar appended to the benzylic hydroxyl function of amino acid residue 6 (Fig. 1) ; a more subtle difference is the stereochemistry at the 4-position of the amino-sugar moiety of the disaccharide. The relationship between the three members of the A82846 family is merely the degree of chlorination of amino acid residues 2 and 6. Orienticin A,9'10) the remaining monochloro-regioisomer, can be obtained either from natural sources, or by the selective monodechlorination of LY264826.8)
The most active memberof this class of antibiotics, LY264826, is tour to eight times more potent than vancomycinand was, therefore, selected as the primary candidate for chemical derivatization ( Table 1 ). The reductive alkylation of LY264826 is accomplished by treating a methanolic solution of the glycopeptide with a slight excess of the desired aldehyde, heating to reflux and adding to the resulting solution a suitable reducing agent, typically sodium cyanoborohydride (Fig.  2) . The progress of the reaction can best be monitored by analytical HPLC,and purification of the products is accomplished by preparative HPLC(C18 reverse phase). The three amino functions of LY264826 are all capable of undergoing reductive alkylation which can result in seven possible products-one tri-, three di-and three mono-alkylated products. Under these reaction conditions, the major product obtained is that resulting from mono-alkylation of the disaccharide amino function (Nl); characteristically, this product is also the first to elute by HPLC.The minor product obtained results from mono-alkylation of the 7V-methylleucine amino function (N2). The reaction conditions can be modified, typically by employing a large excess of aldehyde and longer reaction times, to obtain sufficient quantities of the di-and tri-alkylated products. Wehave not been able to isolate, in pure form, the product resulting from monoalkylation of the mono-saccharide amino function (N3). Fast atom bombardment mass spectroscopy (FAB- results from loss of the disaccharide plus the alkyl group. This fragmentation pattern is uniquely consistent with substitution at Nl (disaccharide amino function).
Results and Discussion Our initial studies focused on determining which of the seven possible 7V-alkyl derivatives of LY264826
exhibited the most potent antimicrobial activity. Table   2 illustrates the various derivatives obtained from the reductive alkylation using />-chlorobenzaldehyde, 4- The di-and tri-7V-alkyl derivatives were equally less active against enterococci than the corresponding Nl mono-alkyl products, while the tri-alkyl compounds were also completely ineffective against staphylococci. Our next objective was to compare the antibiotic activity of the Nl mono-alkylated derivatives of a series of related glycopeptides. Table 3 illustrates the results from the reductive alkylation of the natural glycopeptides with 4-biphenylcarboxaldehyde and 4-butyloxybenzaldehyde. Evaluation of the antibacterial activity of these derivatives provides insights as to the role of the chlorine substituents and the monosaccharide substituted at amino acid residue 6.14'15) Comparing the activity of the vancomycin derivatives (14 and 18) to the LY264826 derivatives (4 and 19) suggests the presence of the monosaccharide on amino acid residue 6 is important for activity against VRE, but does not improve the activity against staphylococci. The importance of the residue 6 chlorine substituent (indicated by X in Fig. 1 ) for activity against enterococci is evident by comparing compounds 15, 16, and 17 to compound 4. Derivatives lacking a chlorine at this position (15 and 16) were found to be 4~8 times less active. On the other hand, loss of the residue 2 chlorine (indicated by Yin Fig. 1 ) had much less of an impact (compound17). It is also important to note that while the di-dechloro derivatives, 16 and 20, are less active against enterococci as compared to the dichloro derivatives, 4 and 19, they are 2~10 times more active against staphylococci. The divergent nature of the SARmay have implications on the mechanismof action of these semisynthetic glycopeptides and warrants further investigation.
Overall, semisynthetic modification of LY264826 provides the most potent activity against VRE and staphylococci. Against VRE, both 4 (LY307599) and 19 (LY309686) were as much as 50 times more active than their parent glycopeptide, and 4~16 times more active than the corresponding derivative of the other glycopeptides.
The present studies indicate that mono-alkylation of In vitro evaluation of activity against enterococci was carried out in a screening assay using broth microdilution in Brain Heart Infusion medium. Strains used were four representitive vancomycin-resistant enterococci (two E. faecium, and two E. faecalis) with confirmed vanA genotypes, and five vancomycin-susceptible isolates (two E. faecium, and three E. faecalis). Comparative data are presented as the range of MIC's (jug/ml).
Experimental Procedures
General Procedure : The glycbpeptide (1 mmol) was dissolved in 150ml of methanol and treated with the aldehyde (1.1 mmol) . The resulting solution was heated to 70°C for 2 hours then treated with NaBH3CN (1.1mmol).
After an additional 2 hours at 70°C, the Heating was continued at 70°C for an additional two hours, after which the mixture was cooled and concentrated in vacuo. Purification of the crude product by preparative HPLC afforded 1.02g (41% yield) of 4. Example 3 : Preparation of N-4'-chloro-4-phenylbenzyl A82846B (9) . A82846B free base (1.0g, 0.628mmol) was dissolved in 100ml of CH3OHand treated with 4/-chlorobiphenyl-4-carboxaldehyde (0.131 g, 0.605 mmol). The resulting mixture was heated to 70°C for 2 hours, then NaBH3CN(46mg, 0.73mmol) was added.
Heating was continued at 70°C for an additional two hours, after whichthe mixture was cooled and concentrated in vacuo. Purification of the crude product by preparative HPLC afforded 0.201 g (18% yield) of 9. Example 4 : Modified procedure for the preparation of 9, 10, ll, 12, and 13 . A82846B free base (0.75g, 0.47mmol) was dissolved in 50ml ofCH3OH-H2O, 1 : 1 (v/v) , and treated with 4'-chlorobiphenyl-4-carboxaldehyde (0.197g, 0.91 mmol) and NaBH3CN (86mg, 1.4mmol). The resulting mixture was heated to reflux for 6.5 hours, after which the mixture was cooled and concentrated in vacuo. HPLCanalysis (area percents, Zorbax SB-C18 column) of the crude reaction mixture afforded 14.9% 9, 21.2% 10, 25.9% ll, 10.5% 12, and 5.0% 13.
HPLC Methods
Analytical : Reactions were monitored by analytical HPLC using a Waters /^Bondapak C18 column (3.9 x 300mm) and UVdetection at 280nm. Elution was accomplished with a linear gradient of 5% CH3CN-95% buffer to 80% CH3CN-20% buffer over 30 minutes. The buffer used was 0.5% triethylamine in water, adjusted to pH 3 with H3PO4. Preparative : Crude reaction mixtures were purified by preparative HPLCusing a Waters C18 Nova-Pak column (40 x 300mm) and UV detection at 280nm. Elution was accomplished with a linear gradient of5% CH3CN-95% JUNE 1996 buffer to 80% CH3CN-20% buffer over 30 minutes. The buffer used was 0.5% triethylamine in water, adjusted to pH 3 with H3PO4. The desired fractions were subsequently desalted with a Waters C18 Sep-Pak (35cc) followed by lyophilization. Alternatively, a buffer containing 0.1% TFA in H2O can be used, in which case the TFAsalt is obtained directly after lyophilization.
FAB-MSAnalysis FAB-MSspectra were determined using a ZAB-2SE mass spectrometer. Samples were dispersed in thioglycerol, with added TFA, and introduced into the mass spectrometer on a FABtarget.
